QuidelOrtho Corporation (QDEL) Cash Flow Statement

The gap between net income and operating cash flow is the central signal here, since losses of this magnitude would normally coincide with cash burn unless large non-cash charges are present. The quarterly D&A of roughly $112M to $120M appears to account for much of the divergence, but the swing in working capital from -$81.6M to +$129.1M across recent quarters indicates that reported operating cash flow is heavily timing-dependent. Investors should monitor whether operating cash flow stabilizes positive once working capital normalizes, as the current pattern warrants further investigation rather than being read as proof of underlying earnings power.

Free cash flow has been positive in only a minority of recent periods, with 2025Q4 at $86.6M and 2025Q1 at $75.7M being the notable exceptions. The lack of a consistent positive trajectory suggests the business is not yet generating self-funding cash at its current revenue base of roughly $619M per quarter. The volatility implies that quarterly FCF is highly sensitive to working capital timing and should be assessed on a rolling multi-quarter basis.

The lower capital intensity in recent quarters may reflect a deliberate pullback following the Quidel-Ortho integration, which would be consistent with a shift toward preserving liquidity. Because D&A substantially exceeds CapEx in every period, the installed instrument base may be depreciating faster than it is being replaced. Whether the reduced spending is sustainable without eroding the placement pipeline for reagent consumables is a question that warrants further investigation.

The magnitude of these swings relative to quarterly operating cash flow suggests that collections, inventory, or payables timing is a major driver of reported results. The reversal from large outflows to a large inflow within a single quarter may reflect year-end collection efforts or inventory adjustments, though the data alone does not establish which. Investors should monitor whether these reversals persist, as recurring dependence on working capital release would weaken the quality of reported cash generation.

Over the observed window, the cumulative net loss substantially exceeds the cumulative operating cash burn, which points to a material share of losses being non-cash, such as impairments or amortization tied to the Ortho acquisition. This does not prove the absence of future cash costs, since integration spending and restructuring outflows may still be ahead. The distinction between accounting losses and cash losses should be tracked closely as the balance sheet is reassessed.